Human glioma immunobiology in vitro: Implications for immunogene therapy

Ian F Parney, Maxine A. Farr-Jones, Lung Ji Chang, Kenneth C. Petruk

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

OBJECTIVE: Human gliomas are known to be immunosuppressive. Recent reports have suggested novel strategies to overcome this immunosuppression, including immunogene therapy. We examined expression of 10 immunologically important molecules by human gliomas in vitro, and we discuss the implications for immunogene therapy. METHODS: Early passage human glioma cultures and established human glioma cell lines were analyzed by flow cytometry for expression of Class I and II major histocompatibility complex (MHC), B7-2 (CD86), and Fas (CD95). Culture supernatants were assayed by enzyme-linked immunosorbent assay for interleukin (IL)-6, IL-10, IL-12, transforming growth factor β2, prostaglandin E2, and granulocyte-macrophage colony-stimulating factor levels. RESULTS: All cultures (16 of 16 samples) expressed Class I MHC and Fas, but few expressed Class II MHC (1 of 16 samples) or B7-2 (0 of 16 samples). Nearly all expressed high levels of IL-6 (19 of 21 samples; mean, 36.5 ± 10.8 ng/106 cells/d) and prostaglandin E2 (21 of 21 samples; mean, 15.6 ± 4.5 ng/106 cells/d) levels, and many expressed transforming growth factor β2 (13 of 21 samples; mean, 8.6 ± 3.7 ng/106 cells/d). Although several cultures (6 of 14 samples) expressed granulocyte-macrophage colony-stimulating factor, expression levels were very low (mean, 0.2 ± 0.1 ng/106 cells/d). Few cultures (4 of 21 samples) expressed measurable IL-10, and none (0 of 22 samples) expressed IL-12. CONCLUSION: Class I MHC and Fas expression suggests that human glioma cells may be susceptible to Class I MHC-dependent cytotoxic T cell recognition and Fas-mediated killing. Unfortunately, transforming growth factor β2 and prostaglandin E2 probably impair T cell activation, and IL-6 may shift immunity to less effective humoral (T helper 2) responses. Proinflammatory gene expression (B7-2, granulocyte-macrophage colony-stimulating factor, and/or IL-12) is lacking. Together, these results suggest that modifying glioma cells via proinflammatory gene transfer or immunoinhibitory gene suppression might stimulate immune responses that are effective against unmodified tumors.

Original languageEnglish (US)
Pages (from-to)1169-1178
Number of pages10
JournalNeurosurgery
Volume46
Issue number5
StatePublished - May 2000
Externally publishedYes

Fingerprint

Glioma
Major Histocompatibility Complex
Transforming Growth Factors
Interleukin-12
Granulocyte-Macrophage Colony-Stimulating Factor
Dinoprostone
Interleukin-6
Interleukin-10
Therapeutics
T-Lymphocytes
Immunosuppressive Agents
Immunosuppression
Genes
In Vitro Techniques
Immunity
Flow Cytometry
Enzyme-Linked Immunosorbent Assay
Gene Expression
Cell Line
Neoplasms

Keywords

  • Cytokine
  • Glioma
  • Immunogene therapy
  • Immunology

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Parney, I. F., Farr-Jones, M. A., Chang, L. J., & Petruk, K. C. (2000). Human glioma immunobiology in vitro: Implications for immunogene therapy. Neurosurgery, 46(5), 1169-1178.

Human glioma immunobiology in vitro : Implications for immunogene therapy. / Parney, Ian F; Farr-Jones, Maxine A.; Chang, Lung Ji; Petruk, Kenneth C.

In: Neurosurgery, Vol. 46, No. 5, 05.2000, p. 1169-1178.

Research output: Contribution to journalArticle

Parney, IF, Farr-Jones, MA, Chang, LJ & Petruk, KC 2000, 'Human glioma immunobiology in vitro: Implications for immunogene therapy', Neurosurgery, vol. 46, no. 5, pp. 1169-1178.
Parney IF, Farr-Jones MA, Chang LJ, Petruk KC. Human glioma immunobiology in vitro: Implications for immunogene therapy. Neurosurgery. 2000 May;46(5):1169-1178.
Parney, Ian F ; Farr-Jones, Maxine A. ; Chang, Lung Ji ; Petruk, Kenneth C. / Human glioma immunobiology in vitro : Implications for immunogene therapy. In: Neurosurgery. 2000 ; Vol. 46, No. 5. pp. 1169-1178.
@article{ff3c14930ac24f668ad1b218f191ab81,
title = "Human glioma immunobiology in vitro: Implications for immunogene therapy",
abstract = "OBJECTIVE: Human gliomas are known to be immunosuppressive. Recent reports have suggested novel strategies to overcome this immunosuppression, including immunogene therapy. We examined expression of 10 immunologically important molecules by human gliomas in vitro, and we discuss the implications for immunogene therapy. METHODS: Early passage human glioma cultures and established human glioma cell lines were analyzed by flow cytometry for expression of Class I and II major histocompatibility complex (MHC), B7-2 (CD86), and Fas (CD95). Culture supernatants were assayed by enzyme-linked immunosorbent assay for interleukin (IL)-6, IL-10, IL-12, transforming growth factor β2, prostaglandin E2, and granulocyte-macrophage colony-stimulating factor levels. RESULTS: All cultures (16 of 16 samples) expressed Class I MHC and Fas, but few expressed Class II MHC (1 of 16 samples) or B7-2 (0 of 16 samples). Nearly all expressed high levels of IL-6 (19 of 21 samples; mean, 36.5 ± 10.8 ng/106 cells/d) and prostaglandin E2 (21 of 21 samples; mean, 15.6 ± 4.5 ng/106 cells/d) levels, and many expressed transforming growth factor β2 (13 of 21 samples; mean, 8.6 ± 3.7 ng/106 cells/d). Although several cultures (6 of 14 samples) expressed granulocyte-macrophage colony-stimulating factor, expression levels were very low (mean, 0.2 ± 0.1 ng/106 cells/d). Few cultures (4 of 21 samples) expressed measurable IL-10, and none (0 of 22 samples) expressed IL-12. CONCLUSION: Class I MHC and Fas expression suggests that human glioma cells may be susceptible to Class I MHC-dependent cytotoxic T cell recognition and Fas-mediated killing. Unfortunately, transforming growth factor β2 and prostaglandin E2 probably impair T cell activation, and IL-6 may shift immunity to less effective humoral (T helper 2) responses. Proinflammatory gene expression (B7-2, granulocyte-macrophage colony-stimulating factor, and/or IL-12) is lacking. Together, these results suggest that modifying glioma cells via proinflammatory gene transfer or immunoinhibitory gene suppression might stimulate immune responses that are effective against unmodified tumors.",
keywords = "Cytokine, Glioma, Immunogene therapy, Immunology",
author = "Parney, {Ian F} and Farr-Jones, {Maxine A.} and Chang, {Lung Ji} and Petruk, {Kenneth C.}",
year = "2000",
month = "5",
language = "English (US)",
volume = "46",
pages = "1169--1178",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Human glioma immunobiology in vitro

T2 - Implications for immunogene therapy

AU - Parney, Ian F

AU - Farr-Jones, Maxine A.

AU - Chang, Lung Ji

AU - Petruk, Kenneth C.

PY - 2000/5

Y1 - 2000/5

N2 - OBJECTIVE: Human gliomas are known to be immunosuppressive. Recent reports have suggested novel strategies to overcome this immunosuppression, including immunogene therapy. We examined expression of 10 immunologically important molecules by human gliomas in vitro, and we discuss the implications for immunogene therapy. METHODS: Early passage human glioma cultures and established human glioma cell lines were analyzed by flow cytometry for expression of Class I and II major histocompatibility complex (MHC), B7-2 (CD86), and Fas (CD95). Culture supernatants were assayed by enzyme-linked immunosorbent assay for interleukin (IL)-6, IL-10, IL-12, transforming growth factor β2, prostaglandin E2, and granulocyte-macrophage colony-stimulating factor levels. RESULTS: All cultures (16 of 16 samples) expressed Class I MHC and Fas, but few expressed Class II MHC (1 of 16 samples) or B7-2 (0 of 16 samples). Nearly all expressed high levels of IL-6 (19 of 21 samples; mean, 36.5 ± 10.8 ng/106 cells/d) and prostaglandin E2 (21 of 21 samples; mean, 15.6 ± 4.5 ng/106 cells/d) levels, and many expressed transforming growth factor β2 (13 of 21 samples; mean, 8.6 ± 3.7 ng/106 cells/d). Although several cultures (6 of 14 samples) expressed granulocyte-macrophage colony-stimulating factor, expression levels were very low (mean, 0.2 ± 0.1 ng/106 cells/d). Few cultures (4 of 21 samples) expressed measurable IL-10, and none (0 of 22 samples) expressed IL-12. CONCLUSION: Class I MHC and Fas expression suggests that human glioma cells may be susceptible to Class I MHC-dependent cytotoxic T cell recognition and Fas-mediated killing. Unfortunately, transforming growth factor β2 and prostaglandin E2 probably impair T cell activation, and IL-6 may shift immunity to less effective humoral (T helper 2) responses. Proinflammatory gene expression (B7-2, granulocyte-macrophage colony-stimulating factor, and/or IL-12) is lacking. Together, these results suggest that modifying glioma cells via proinflammatory gene transfer or immunoinhibitory gene suppression might stimulate immune responses that are effective against unmodified tumors.

AB - OBJECTIVE: Human gliomas are known to be immunosuppressive. Recent reports have suggested novel strategies to overcome this immunosuppression, including immunogene therapy. We examined expression of 10 immunologically important molecules by human gliomas in vitro, and we discuss the implications for immunogene therapy. METHODS: Early passage human glioma cultures and established human glioma cell lines were analyzed by flow cytometry for expression of Class I and II major histocompatibility complex (MHC), B7-2 (CD86), and Fas (CD95). Culture supernatants were assayed by enzyme-linked immunosorbent assay for interleukin (IL)-6, IL-10, IL-12, transforming growth factor β2, prostaglandin E2, and granulocyte-macrophage colony-stimulating factor levels. RESULTS: All cultures (16 of 16 samples) expressed Class I MHC and Fas, but few expressed Class II MHC (1 of 16 samples) or B7-2 (0 of 16 samples). Nearly all expressed high levels of IL-6 (19 of 21 samples; mean, 36.5 ± 10.8 ng/106 cells/d) and prostaglandin E2 (21 of 21 samples; mean, 15.6 ± 4.5 ng/106 cells/d) levels, and many expressed transforming growth factor β2 (13 of 21 samples; mean, 8.6 ± 3.7 ng/106 cells/d). Although several cultures (6 of 14 samples) expressed granulocyte-macrophage colony-stimulating factor, expression levels were very low (mean, 0.2 ± 0.1 ng/106 cells/d). Few cultures (4 of 21 samples) expressed measurable IL-10, and none (0 of 22 samples) expressed IL-12. CONCLUSION: Class I MHC and Fas expression suggests that human glioma cells may be susceptible to Class I MHC-dependent cytotoxic T cell recognition and Fas-mediated killing. Unfortunately, transforming growth factor β2 and prostaglandin E2 probably impair T cell activation, and IL-6 may shift immunity to less effective humoral (T helper 2) responses. Proinflammatory gene expression (B7-2, granulocyte-macrophage colony-stimulating factor, and/or IL-12) is lacking. Together, these results suggest that modifying glioma cells via proinflammatory gene transfer or immunoinhibitory gene suppression might stimulate immune responses that are effective against unmodified tumors.

KW - Cytokine

KW - Glioma

KW - Immunogene therapy

KW - Immunology

UR - http://www.scopus.com/inward/record.url?scp=0034018970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034018970&partnerID=8YFLogxK

M3 - Article

C2 - 10807250

AN - SCOPUS:0034018970

VL - 46

SP - 1169

EP - 1178

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 5

ER -